601607 上海医药
2024/06 - 中期
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
2021/12
人民币(K¥)
2020/12
人民币(K¥)
经营活动产生之现金流量净额515,3035,231,5204,743,3615,061,3266,844,721
投资活动产生之现金流量净额2,033,178(2,491,873)(12,473,124)(6,015,576)(1,705,676)
筹资活动产生之现金流量净额3,763,100231,85112,138,5941,565,628(1,261,230)
汇率变动对现金及现金等价物的影响(8,187)(5,580)(12,440)(50,323)(17,628)
现金及现金等价物净增加/(减少)6,303,3942,965,9184,396,391561,0553,860,187
期初现金及现金等价物余额27,499,80924,533,89120,137,50019,576,44515,716,258
期末现金及现金等价物余额33,803,20327,499,80924,533,89120,137,50019,576,445